Please assess the completion status of the following clinical trial:

Trial Title: Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 months to 30 years~* Individuals clinically planned for elective surgical Ebstein repair~* Individuals able to undergo bone marrow aspirate according to clinical consultation with Hematology (cell treatment group only)~* Individuals able to undergo preoperative MRI or CT examination~* Individual and/or parent willing and able to give informed consent and willing to commit to completion of follow-up~Exclusion Criteria:~* Individuals requiring cavopulmonary shunt at the time of surgical Ebstein repair; planned preoperatively or required intraoperatively~* Individuals with, or reasonably expected to have, complications during surgical Ebstein repair or during post-operative recovery~* Individual who have not completed or will not be completing all pre-procedure work-up within 30 days of surgical Ebstein repair AND lack of pre-procedure work-up documented as a safety concern by a site investigator~* Individuals who have other clinical concerns as documented by a site investigator that could reasonably increase the risk of complications during or after surgical Ebstein repair~* Individuals whose cells have been determined, by the sponsor, to not be acceptable for release to the investigational site or individual whose cells have been compromised after cells released to investigational site (cell treatment group only)~* Individuals who require surgery on pulmonary, mitral, or aortic valve~* Individuals with pulmonary atresia or atrioventricular discordance with ventriculoarterial discordance~* Individuals with history of ventricular arrhythmia or new onset ventricular arrhythmia after enrollment that requires medical management~* Individuals who have undergone previous sternotomy~* Individuals with preoperative ventricular arrhythmia requiring medical management~* Individuals with severe chronic diseases, extensive extra-cardiac syndromes, or history of any cancer~* Individuals with current IV inotrope requirements~* Individuals with bleeding disorders or history of thrombosis~* Subjects not eligible for MRI or CT examination due to either a medical contraindication, including acute or chronic renal failure~* Individuals with a currently active infection being treated with oral antibiotics~* Individuals with the following conditions within 60 days prior to Ebstein repair surgery:~  * Cardiogenic shock or extracorporeal circulation~ * Documented infection requiring treatment with intravenous antibiotics~ * Cardiac condition requiring emergency procedure~ * Current or uncontrolled seizures or neurological injury that has resulted in a persistent deficit~ * Multi-system organ failure including acute or chronic renal failure~* Female subjects 10 years and older with positive pregnancy test or lack of effective birth control method during the 30 days prior to surgical Ebstein repair~* Individuals who weigh more than 90 kg

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention using an add-on procedure delivering autologous bone marrow-derived mononuclear cells into the right ventricle.
- Control arm (Type: OTHER): Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention without cell delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete